Released on: May 17, 2008, 1:17 am

Press Release Author: Intas Biopharmaceuticals Limited

Industry: Biotech

Press Release Summary: Intas Biopharmaceuticals Limited, an Ahmedabad-based
biopharmaceutical company, has chalked elaborate marketing plans for its global and
domestic operations for this fiscal. The company engaged in R&D, Manufacturing and
Marketing of biotech drugs, signed supply agreement in Africa to consolidate its
position in "Middle East North Africa" region. Initially, the company is looking to
supply and market three products - Neukine®, Erykine® and Intalfa® and at a later
stage, it can expand its operations in the region. With this agreement in place,
Intas Biopharmaceuticals, now has its reach in Morocco, Algeria, West Africa (Ivory
Coast, Senegal, Mali, Cameroon), Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the
United Arab Emirates.

Press Release Body: Sharing the marketing plans for MENA region, Mr. Simon Daniel,
Chief Executive (Marketing), said, "The supply agreement in Africa gives a strategic
advantage to IBPL in strengthening its market position in MENA region and serves the
goal of reaching new destinations. The technology strength of IBPL and market
intelligence/distribution network of our local partner in Africa can be unified for
providing the much-needed boost to establish business rapidly. We are looking
forward to more agreements with leading international pharmaceutical/biotech
companies in future to expand our market reach of products.

The epidemiological trends of MENA region combined with high population growth, the
current socio economical situation along with the improvement of educational level
are as many elements in favour, not only of a growing need for biotech products and
services in the region in the near future, but also for an equitable access to such
products and services."

With recently announced agreement in North America for Neukine®, IBPL's reach has
extended to every continent and geographical region. This business deal brings
together two companies, with complimentary strengths and niche expertise, which will
help in launching the first GCSF generic in North America. After EU GMP
certification, the entry into semi-regulated markets has become relatively easy for
IBPL as the quality conscious Pharma/Biotech companies are assured of superior
quality of products and services. Amongst regulated/semi-regulated markets, IBPL
offers an edge over its competitors in terms of unique pricing, products, services
and its marketing strategy. With unique capabilities of R&D, Manufacturing and
Marketing, IBPL has significant presence in Europe, Asia-Pacific, Middle East,
Russia & CIS, South and Central America and Africa.

Further elaborating on company's future prospects, Mr. Simon Daniel said, "IBPL is
looking to consolidate its position in the Contract Research and Manufacturing
Services (CRAMS) segment. The company has taken up CRAMS opportunity as a focus area
with tremendous potential and are preparing to scale up the facilities. With respect
to CRAMS, IBPL offers a unique business model for offshore clients from
regulated/semi-regulated markets and has competitive advantage in terms of
developing new biotech products, technology transfer and contract manufacturing at
committed costs, quality and time to create a competitive advantage for the company.
With growing business opportunities, IBPL will find itself in the best position to
plan certain key initiatives in the coming financial year."

Speaking on IBPL's domestic operations, Mr. Daniel said, "In order to give impetus
to IBPL's sales activities, the company plans to launch new sales division BRIDGE
catering to Nephrology / Neurology therapeutic areas. IBPL is the only Indian
biotech company to manufacture Pegylated GCSF and market it under the brand name
NeupegT. The product offers treatment against toxicity caused due to chemotherapy in
cancer patients. This USP has prompted the need for a special and dedicated sales
division RELAY. IBPL has doubled its sales force to allow more focussed approach
towards niche therapeutic areas of Oncology. Keeping in view the future product
pipeline, increasing the sales force is an important step towards strengthening
IBPL's presence in the domestic market."

Intas entered the Indian anti-cancer market in the year 1998 with the launch of
Novatech division (oncology marketing division). Starting with a product basket of a
few oncology products in 1999, today, IBPL can boast of one of the most
comprehensive oncology product basket comprising of 26 products in different dosage
forms (capsules, injections, tablets and pre-filled syringes).

Web Site: http://www.intasbiopharma.co.in

Contact Details: Siddharth J. Baad
Plot No. 423/P/A/GIDC, Sarkhej-Bavla Highway
Moraiya, Tal: Sanand, Ahmedabad - 382 210 INDIA
Tel: (02717) - 660100/660101; Fax: (02717) - 251189